Trial
NCT01912404
Study of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Steroid Therapy
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Conatus Pharmaceuticals Inc.
Collaborators
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Condition
Alcoholic Hepatitis
Intervention
IDN-6556
Why stopped
Due to concern for high systemic drug levels that could exceed levels in toxicology studies.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-11-04